Table 4.
Regional 5-HT synthesis ratesa (mean± SD [pmol/g/min]) in OBX rats treated with either vehicle (XVV), citalopram alone (XCV) or in combination with pindolol (XCP).
| Region† | Predominant Nucleus of Origin | XVVa (n=10) |
XCVa (n=7) |
% change in XCV relative to XVV | XCPa (n=8) |
% change in XCP relative to XCV |
|---|---|---|---|---|---|---|
| aPCX | DR | 39 ± 5 | 33 ± 5 | ns | 45 ± 16 | ns |
| pPCX | DR | 37 ± 7 | 46 ± 4 | 25* | 53 ± 8 | ns |
| FCX | DR | 27 ± 7 | 24 ± 6 | ns | 57 ± 6 | 138# |
| SCX | DR | 23 ± 7 | 24 ± 9 | ns | 50 ± 6 | 107# |
| AudCX | DR | 25 ± 7 | 30 ± 10 | ns | 54 ± 7 | 83# |
| VCX | DR | 28 ± 7 | 28 ± 9 | ns | 60 ± 6 | 112# |
| BNST | DR | 37 ± 8 | 31 ± 6 | ns | 56 ± 9 | 79# |
| Nacc | DR | 54 ± 8 | 41 ± 7 | -24* | 56 ± 14 | 37# |
| CPL | DR | 31 ± 8 | 28 ± 7 | ns | 51 ± 6 | 81# |
| CPM | DR | 43 ± 8 | 34 ± 6 | ns | 60 ± 9 | 80# |
| CPV | DR | 42 ± 8 | 36 ± 6 | ns | 65 ± 10 | 82# |
| GP | DR | 30 ± 7 | 31 ± 4 | ns | 45 ± 7 | 45# |
| AC-Amyg | DR | 38 ± 6 | 39 ± 4 | ns | 55 ± 10 | 42# |
| CN-Amyg | DR | 38 ± 7 | 36 ± 6 | ns | 59 ± 9 | 64# |
| BLN-Amyg | DR | 44 ± 8 | 44 ± 7 | ns | 62 ± 11 | 41# |
| PV-Thal | DR | 36 ± 8 | 37 ± 7 | ns | 51 ± 7 | 40# |
| SNc | DR | 34 ± 6 | 27 ± 6 | -20* | 50 ± 5 | 83# |
| LC | DR | 33 ± 8 | 29 ± 7 | ns | 52 ± 7 | 78# |
| MOA | MR | 50 ± 9 | 30 ± 5 | -40* | 45 ± 22 | ns |
| MOCX | MR | 39 ± 7 | 29 ± 11 | ns | 49 ± 13 | 67# |
| IFLCX | MR | 44 ± 8 | 25 ± 9 | -42* | 53 ± 9 | 108# |
| CgCX | MR | 31 ± 7 | 24 ± 7 | ns | 54 ± 7 | 131# |
| SCH | MR | 44 ± 9 | 25 ± 12 | -42* | 76 ± 6 | 198# |
| Hipp-d | MR | 37 ± 7 | 32 ± 10 | ns | 57 ± 11 | 78# |
| DG | MR | 38 ± 7 | 31 ± 8 | ns | 54 ± 11 | 75# |
| CA3 | MR | 43 ± 7 | 37 ± 8 | ns | 65 ± 9 | 77# |
| DR | 111 ± 5 | 61 ± 13 | -45* | 107 ± 25 | 76# | |
| MR | 78 ± 4 | 43 ± 6 | -45* | 70 ± 13 | 63# | |
†
Region names are abbreviated under Table 2.
*
Significant difference between XVV and XCV groups.
#
Significant difference between XCV and XCP groups.
ns, not significant.